MedTrace Logo

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

NCT01465360 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2012-07-06

No results posted yet for this study

Summary

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory impairments.

Conditions

Sponsors & Collaborators

  • Exonhit

    lead INDUSTRY

Principal Investigators

  • Charles B. Bernick, MD · Cleveland Clinic Lou Ruvo Center for Brain Health

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01465360 on ClinicalTrials.gov